ClinicalTrials.gg
CompletedNCT00928707PVUpdated Oct 31, 2019Results posted

Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera

A Phase 2 interventional study of GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea and GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea in Polycythemia Vera, sponsored by Italfarmaco. Completed at 22 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Polycythemia Vera with a site in Italy — 8 open to participants now, 15 under way, 3 of them phase 3. Polycythemia Vera · Italy.

Enrollment
27th of 31
45 · median 127
Started
2009
the only one that year
Phase 2
11 of 44
none open now
Registered
10th of 44
by date
Lead sponsor
5 of 44
Italfarmaco

Among the 44 studies in Polycythemia Vera with a site in Italy, this one is the 27th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2009, is one of 11 in phase 2, and was the 10th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

8 of the 44 studies in Polycythemia Vera with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Polycythemia Vera with a site in Italy, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy.

The secondary objectives of this study were:

  • To evaluate the safety and tolerability of Givinostat in combination with hydroxyurea in patients with JAK2V617Fpositive PV non-responders to the maximum tolerated dose of hydroxyurea monotherapy;
  • To explore the impact in terms of efficacy and tolerability of Givinostat 50 mg dose escalation in patients not achieving at least a partial response at the time when the primary endpoint was assessed (week 12);
  • To evaluate the molecular response (JAK2 mutated allele burden) by quantitative Real Time-Polymerase Chain Reaction (RT-PCR);
  • To evaluate the reduction of the fraction of JAK2V617F positive clonogenic progenitors.
Read the detailed description

This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.

Recruited patients will be randomly assigned to one of the following treatment groups:

  • group A: 50 mg o.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study;
  • group B: 50 mg b.i.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study.

The two groups will be balanced for number and for Centre in order to provide valuable information on both treatment regimens.

In both groups assigned doses shall remain stable until week 12, which is when the primary endpoint is assessed, unless specific tolerability issues arise which impose dose reduction.

After the primary endpoint assessment at week 12, one of the following treatment schedules will be chosen case by case on the basis of the achieved clinical response and continued for up to 12 further weeks:

  • Partial or Complete Response at week 12:
  • group A: continue 50 mg o.d.;
  • group B: continue 50 mg b.i.d.;
  • No Response at week 12:
  • group A: increase to 50 mg b.i.d.;
  • group B: increase to 50 mg t.i.d.. At any time during study course, if toxicity is observed, GIVINOSTAT (ITF2357) treatment will be discontinued until recovery and then restarted at a reduced dose level. The drug will be definitively withdrawn in case of reappearance of toxicity even at a reduced daily dose. Overall, the treatment will last up to a maximum of 24 cumulative weeks of drug administration.

The study will recruit subjects of both genders with an established diagnosis of JAK2V617F positive Polycythemia Vera according to the revised WHO criteria, in need of cytoreductive therapy, non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • Polycythemia Vera
  • GIVINOSTAT
  • ITF2357
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Age ≥18 years.
  • Confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization (WHO) criteria.
  • JAK2V617F positivity.
  • Non-response to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.
  • (Eastern Cooperative Oncology Group) performance status \<3.
  • Use of an effective means of for women of and men with partners of childbearing potential.
  • Willingness and capability to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Active bacterial or mycotic infection requiring antimicrobial treatment.
  • Pregnancy or lactation.
  • A marked baseline prolongation of /QTc (corrected) interval (e.g. repeated demonstration of a QTc interval > 450 ms, according to Bazett's correction formula).
  • Use of concomitant medications that prolong the QT/QTc interval.
  • cardiovascular disease including:

    • Uncontrolled hypertension, myocardial infarction, unstable angin, within 6 months from study start;
    • (NYHA) Grade II or greater congestive heart failure;
    • History of any cardiac arrhythmia requiring medication (irrespective of its severity);
    • A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Positive blood test for (Human Immunodeficiency Virus)
  • Active (Hepatitis B Virus) and/or (Hepatitis C Virus) infection.
  • count \<100x109/L within 14 days before enrolment.
  • \<1.2x109/L within 14 days before enrolment.
  • Serum creatinine >2xULN ().
  • Total serum >1.5xULN.
  • Serum (AST) / alanine aminotransferase (ALT) > 3xULN.
  • History of other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications.
  • Interferon alpha within 14 days before enrolment.
  • Anagrelide within 7 days before enrolment.
  • Any other investigational drug within 28 days before enrolment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    GIVINOSTAT + MTD Hydroxyurea (HU)_1

    50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy

    Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea

  • Experimental
    GIVINOSTAT + MTD Hydroxyurea (HU)_2

    50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy

    Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea

Interventions

  • DrugGIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea

    Drug page: Givinostat

    50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy

    Also known as: GIVINOSTAT (ITF2357), ONCOCARBIDE (HYDROXYUREA)

  • DrugGIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea

    Drug page: Givinostat

    50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy

    Also known as: GIVINOSTAT (ITF2357), ONCOCARBIDE (HYDROXYUREA)

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Overall Haematological Response at Week 12.

    The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.

    Time frame: At week 12 of treatment

Secondary outcomes

  1. Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12.

    Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response.

    Time frame: At week 24 of treatment

  2. Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR

    To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).

    Time frame: At weeks 12, 24, at "drop out visit" and at "End of Study" (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24.

  3. Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints

    JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)

    Time frame: Baseline, at weeks 12 and 24

07

Results

Posted Oct 31, 2019

Participant flow

Participant flow — Overall Study
MilestoneGIVINOSTAT +Maximum Tolerated Dose (MTD) of Hydroxyurea (HU)_1GIVINOSTAT +Maximum Tolerated Dose (MTD) of Hydroxyurea (HU)_2
Started2322
Completed2222
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Patients With Overall Haematological Response at Week 12.

The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.

Time frame:
At week 12 of treatment
Reported as:
Number · percentage of particpants
Percentage of Patients With Overall Haematological Response at Week 12.
percentage of particpantsGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
Responder54.5 (33.7 to 75.4)50.0 (29.1 to 70.9)
Non responder45.5 (24.6 to 66.3)50.0 (29.1 to 70.9)
SecondaryPercentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12.

Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response.

Time frame:
At week 24 of treatment
Reported as:
Number · percentage of participants
Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12.
percentage of participantsGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
Responder63.6 (43.5 to 83.7)40.9 (20.4 to 61.5)
Non responder36.4 (16.3 to 56.5)59.1 (38.5 to 79.6)
SecondaryChange From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR

To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).

Time frame:
At weeks 12, 24, at "drop out visit" and at "End of Study" (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24.
Reported as:
Mean · percent change
Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR
percent changeGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
Week 12-2.6 ± 8.20.00 ± 6.0
Week 24-3.8 ± 11.54.6 ± 5.7
Drop-out-4.0 ± 0.00-9.5 ± 20.5
EOS-3.8 ± 11.13.0 ± 8.6
SecondaryPercentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints

JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)

Time frame:
Baseline, at weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints
percentage of participantsGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
Baseline - heterozygous27.322.7
Baseline - homozygous72.772.7
Baseline - not done04.5
week 12 - heterozygous25.031.6
week 12 - homozygous70.063.2
week 12 - not done5.05.3
week 24 - heterozygous22.211.1
week 24 - homozygous72.277.8
week 24 - not done5.611.1

Adverse events

Collected over Adverse events (AEs) were recorded at weeks 1 ,3, 6, 9, 12, 16, 20 or end of treatment visit (week 24 or 7 days after last drug intake). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GIVINOSTAT + MTD Hydroxyurea_10/22 (0%)2/22 (9.1%)21/22 (95.5%)
GIVINOSTAT + MTD Hydroxyurea_20/22 (0%)1/22 (4.5%)21/22 (95.5%)
Most frequent serious events
Most frequent serious events
EventGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
AppendicectomySurgical and medical procedures1/220/22
EmbolismRespiratory, thoracic and mediastinal disorders1/220/22
Pregnancy of partnerSocial circumstances0/221/22
Most frequent other events
Showing 10 of 68
Most frequent other events
EventGIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2
DiarrhoeaGastrointestinal disorders10/227/22
ThrombocytopeniaBlood and lymphatic system disorders5/227/22
Blood creatinine increasedInvestigations3/222/22
Abdominal painGastrointestinal disorders3/221/22
Abdominal pain upperGastrointestinal disorders2/223/22
NauseaGastrointestinal disorders3/220/22
InfluenzaInfections and infestations3/221/22
HypertensionVascular disorders0/222/22
AstheniaGeneral disorders2/222/22
FatigueGeneral disorders2/221/22

Baseline characteristics

Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.

Age, Categorical
Age, Categorical(Participants)GIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2Total
<=18 years000
Between 18 and 65 years101121
>=65 years131124
Sex: Female, Male
Sex: Female, Male(Participants)GIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2Total
Female9716
Male141529
Region of Enrollment
Region of Enrollment(participants)GIVINOSTAT + MTD Hydroxyurea_1GIVINOSTAT + MTD Hydroxyurea_2Total
Italy232245
08

Study locations

22 sites
  • Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari
    Bari, BA 70124, Italy
  • Azienda Ospedaliera Santa Croce e Carle di Cuneo
    Cuneo, CN 12100, Italy
  • Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania
    Catania, CT 95126, Italy
  • Fondazione I. R. C. C. S. - Casa sollievo della sofferenza di San Giovanni Rotondo
    San Giovanni Rotondo, FG 71013, Italy
  • Azienda Ospedaliero-Universitaria Careggi di Firenze
    Florence, FI 50134, Italy
  • Azienda Ospedaliera San Gerardo di Monza
    Monza, MB 20052, Italy
  • Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino" di Messina
    Messina, ME 98125, Italy
  • Azienda Ospedaliera Ospedali Riuniti "Villa Sofia - Cervello" di Palermo
    Palermo, PA 90146, Italy
  • Azienda Unità Sanitaria Locale di Pescara, Presidio Ospedaliero "Spirito Santo"
    Pescara, PE 65124, Italy
  • Azienda Ospedaliera Santa Maria della Misericordia di Perugia
    Perugia, PG 06156, Italy
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, PI 56126, Italy
  • Azienda Ospedaliera Ospedale San Carlo di Potenza
    Potenza, Point 85100, Italy
  • Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia
    Pavia, PV 27100, Italy
  • Azienda Ospedaliera "Bianchi-Melacrino-Morelli"
    Reggio di Calabria, RC 891225, Italy
  • Azienda Ospedaliera Universitaria S. Luigi Gonzaga di Orbassano
    Orbassano, TO 10043, Italy
  • Azienda Ospedaliero-Universitaria San Giovanni Battista("Le Molinette") di Torino
    Torino, TO 10126, Italy
  • Ospedale Mauriziano Umberto I
    Torino, TO 10128, Italy
  • Ospedale San Bortolo di Vicenza
    Vicenza, VI 36100, Italy
  • Azienda Ospedaliera Ospedali Riuniti di Bergamo
    Bergamo, 24100, Italy
  • Azienda Ospedaliera Universitaria Università degli Studi di Napoli Federico II
    Napoli, 80131, Italy
  • Università "Campus Bio-Medico", Rome
    Rome, 00128, Italy
  • Policlinico Universitario Agostino Gemelli di Roma
    Rome, 00168, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jul 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 8 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2009
First posted
Jun 26, 2009
Start
Jun 2009
Primary completionActual
Jul 2011
CompletionActual
Oct 2011
Results first posted
Oct 31, 2019
Last update
Oct 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00928707
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Jun 2009
Primary completion
Jul 2011
Completion
Oct 2011
Results posted
Oct 31, 2019
Last update
Oct 31, 2019

Study contacts

Alessandro Rambaldi, MD
principal investigator · Azienda Ospedaliera Ospedali Riuniti di Bergamo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion